When it comes to barriers to entry associated with mid-cap and the smaller of the large-cap stocks, few if any companies enjoy the competitive advantage possessed by Edwards Lifesciences. The company operates in the incredibly regulated field of aortic valve replacements and surgical heart valve therapy.
One of its well-established and fast-growing products is the Transcatheter Aortic Valve Replacement (TAVR), and the companies’ Sapien 3 valves exhibit the lowest rate of death, stroke, or rehospitalization among its users. The Sapien 3 is a valve made out of cow tissue that is attached to a balloon-expandable, cobalt-chromium frame for support.
What I find noteworthy (from an investment point of view) about the Sapien 3 … Read the rest of this article!